Flash FinanceUS
Market closed S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · ADMA Biologics (ADMA)

ADMA Biologics Q1 revenue rises 40% to $114.8 million; raises revenue guidance

Positive Impact 4 of 5 earnings Written later

ADMA Biologics reported first-quarter 2025 revenue of $114.8 million, up 40% from a year earlier, and GAAP net income of $26.9 million, up 51%. The company raised its 2025 total revenue guidance to more than $500 million and its 2026 guidance to $625 million or more, and its board authorized a share repurchase program of up to $500 million with no expiration date.

Key points

  • Q1 2025 revenue was $114.8 million versus $81.9 million in Q1 2024; GAAP net income was $26.9 million versus $17.8 million.
  • FY 2025 total revenue guidance was raised to more than $500 million; FY 2026 total revenue guidance was raised to $625 million or more.
  • The board authorized a share repurchase program of up to $500 million, which the filing says has no expiration date.
  • On May 5, 2025 the company borrowed $30.0 million under its Ares revolving credit facility and used it to repay $30.0 million of its term loan; $2.5 million of the term loan remains outstanding.

The filing

CompanyADMA Biologics (ADMA)
Form8-K, current report
Filed with the SECMay 7, 2025, 4:12 PM ET
Accession number0001140361-25-017704

Items reported: 2.02 Results of Operations8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:49 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 07, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.